Aeterna Zentaris Inc. (AEZS)
NASDAQ: AEZS · IEX Real-Time Price · USD
1.950
-0.040 (-2.01%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Aeterna Zentaris Revenue
In the year 2023, Aeterna Zentaris had annual revenue of $4.50M, a decrease of -20.25%. Revenue in the quarter ending December 31, 2023 was $121.00K, a -95.13% decrease year-over-year.
Revenue (ttm)
$4.50M
Revenue Growth
-20.25%
P/S Ratio
2.11
Revenue / Employee
$374,833
Employees
12
Market Cap
9.50M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.50M | -1.14M | -20.25% |
Dec 31, 2022 | 5.64M | 380.00K | 7.22% |
Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
Dec 31, 2019 | 532.00K | -26.35M | -98.02% |
Dec 31, 2018 | 26.88M | 25.96M | 2,812.35% |
Dec 31, 2017 | 923.00K | 12.00K | 1.32% |
Dec 31, 2016 | 911.00K | 366.00K | 67.16% |
Dec 31, 2015 | 545.00K | 534.00K | 4,854.55% |
Dec 31, 2014 | 11.00K | -6.16M | -99.82% |
Dec 31, 2013 | 6.18M | 4.12M | 200.78% |
Dec 31, 2012 | 2.05M | -2.65M | -56.37% |
Dec 31, 2011 | 4.71M | -23.00M | -83.02% |
Dec 31, 2010 | 27.70M | -35.53M | -56.19% |
Dec 31, 2009 | 63.24M | 24.76M | 64.35% |
Dec 31, 2008 | 38.48M | -3.59M | -8.53% |
Dec 31, 2007 | 42.07M | 3.27M | 8.43% |
Dec 31, 2006 | 38.80M | -6.01M | -13.42% |
Dec 31, 2005 | 44.81M | 1.84M | 4.28% |
Dec 31, 2004 | 42.97M | -75.77M | -63.81% |
Dec 31, 2003 | 118.74M | 40.81M | 52.37% |
Dec 31, 2002 | 77.93M | 44.22M | 131.18% |
Dec 31, 2001 | 33.71M | 27.24M | 420.84% |
Dec 31, 2000 | 6.47M | 1.73M | 36.49% |
Dec 31, 1999 | 4.74M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molecular Templates | 57.31M |
Telesis Bio | 27.51M |
NeuroMetrix | 5.90M |
Vaccinex | 570.00K |
BioCardia | 477.00K |
Organovo Holdings | 242.00K |
Kazia Therapeutics | 15.65K |
AEZS News
- 4 weeks ago - Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris - GlobeNewsWire
- 4 weeks ago - Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire
- 2 months ago - Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company - GlobeNewsWire
- 2 months ago - Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro - GlobeNewsWire
- 4 months ago - AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders - Business Wire
- 4 months ago - Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company - GlobeNewsWire
- 9 months ago - Aeterna Zentaris Reports Second Quarter 2023 Financial Results - GlobeNewsWire
- 10 months ago - Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update - GlobeNewsWire